INTRODUCTION
============

In 1906, Alois Alzheimer identified neuritic plaques and neurofibrillary tangles (NFTs) as prominent neuropathologic features in the brains of certain patients, and the pattern was eventually called Alzheimer's disease (AD; [@b29-molce-40-9-613]). In the 1980s, amyloid β-peptide (Aβ) and hyperphosphorylated tau (pTau) were recovered as major components of, respectively, neuritic plaques and NFTs of AD ([@b32-molce-40-9-613]; [@b44-molce-40-9-613]; [@b47-molce-40-9-613]; [@b50-molce-40-9-613]; [@b59-molce-40-9-613]). The amyloid hypothesis proposes that deposition of Aβ plaques in the brain is the primary cause of AD ([@b35-molce-40-9-613]; [@b36-molce-40-9-613]). However, histologically determined numbers of insoluble Aβ plaques in the brain do not correlate with dementia severity ([@b36-molce-40-9-613]; [@b20-molce-40-9-613]). Rather, the tau pathology observed in AD brains correlates better with the degree of cognitive decline ([@b36-molce-40-9-613]; [@b81-molce-40-9-613]). Multiple studies strongly suggest that abnormal elevation in pTau is necessary but not sufficient to cause AD ([@b41-molce-40-9-613]; [@b43-molce-40-9-613]; [@b64-molce-40-9-613]), so what does cause it? This review provides the current understanding of the proteolytic processing of β-amyloid precursor protein (APP), the functional roles of APP-derived fragments, and AD-causing mutations, and it discusses the molecular and cellular mechanisms that underlie the pathogenesis of neurodegenerative AD.

PROTEOLYTIC PROCESSING OF β-AMYLOID PRECURSOR PROTEIN
=====================================================

Aβs, which largely consist of peptides that are 40 and 42 amino acids long (Aβ40 and Aβ42), are produced by sequential APP proteolytic processes by β-secretase (BACE) and γ-secretase ([Figs. 1A and 1B](#f1-molce-40-9-613){ref-type="fig"}; [@b22-molce-40-9-613]; [@b28-molce-40-9-613]; [@b71-molce-40-9-613]); Aβ42 is more aggregation-prone and more neurotoxic than Aβ40 ([@b45-molce-40-9-613]; [@b48-molce-40-9-613]). In the amyloidogenic pathway, human APP is first cleaved by β-secretase, generating a large soluble ectodomain (sAPPβ) and the C-terminal C99 peptide ([Fig. 1B](#f1-molce-40-9-613){ref-type="fig"}), and proteolytic cleavages of the C99 peptide by γ-secretase release Aβs and the APP intracellular domain (AICD; [Figs. 1B](#f1-molce-40-9-613){ref-type="fig"} and [2](#f2-molce-40-9-613){ref-type="fig"}). Alternatively, in the non-amyloidogenic pathway, human APP is sequentially cleaved by α-secretase and γ-secretase, creating a soluble ectodomain (sAPPα), P3 peptide, and the AICD ([Fig. 1B](#f1-molce-40-9-613){ref-type="fig"}). P3 peptide corresponds to Aβ17-40 and Aβ17-42 and is non-amyloidogenic ([Fig. 2](#f2-molce-40-9-613){ref-type="fig"}; [@b75-molce-40-9-613]). Therefore, α- and β-secretases have opposing effects on generating Aβs due to their competitive cleavages of APP. In support of this, increased α-secretase activity through protein kinase C stimulation decreases Aβ generation ([@b42-molce-40-9-613]; [@b56-molce-40-9-613]; [@b79-molce-40-9-613]), whereas *BACE1* knockout mice lack brain Aβs ([@b8-molce-40-9-613]; [@b58-molce-40-9-613]). γ-Secretase, a multi-protein complex that consists of at least four subunits---presenilin (PS), nicastrin, Aph-1, and Pen-2---functions as a transmembrane aspartyl protease that plays a critical role in not only generating Aβs but also determining Aβ42 to Aβ40 ratios ([@b2-molce-40-9-613]; [@b18-molce-40-9-613]; [@b22-molce-40-9-613]). Consistent with this notion, *PS1/PS2* double-null mutation resulted in the absence of Aβ production and complete inactivation of γ-secretase ([@b38-molce-40-9-613]; [@b96-molce-40-9-613]). The γ-secretase-mediated processing of APP is one of the best-characterized examples for regulated intra-membrane proteolysis (RIP) that is an evolutionarily conserved mechanism from bacteria to humans ([@b7-molce-40-9-613]). RIP of APP can be directly modulated by several γ-secretase associated proteins including TMP21, pigeon homologue protein, and proton myo-inositol cotransporter ([@b12-molce-40-9-613]; [@b37-molce-40-9-613]; Teranishi et al., 2015; [@b89-molce-40-9-613]; [@b97-molce-40-9-613]). Because the known prerequisite for a γ-secretase substrate is the release of its bulky extracellular domain ([@b22-molce-40-9-613]; [@b83-molce-40-9-613]), another regulation is indirectly mediated by competitive α-secretase and β-secretase functions that are required for shedding the APP extracellular domain. Therefore, RIP of APP by these secretases is responsible for Aβ production, and it also plays a critical role in determining the ratio of Aβ42 to Aβ40. Understanding the regulatory mechanisms and alterations in RIP of APP in AD patients is necessary for identifying novel therapeutic targets for treating AD.

PROTEOLYTIC FRAGMENTS OF β-AMYLOID PRECURSOR PROTEIN
====================================================

Emerging evidence suggests that soluble Aβ oligomers are the major neurotoxic species and are responsible for the progressive neurodegeneration in AD ([@b51-molce-40-9-613]; [@b55-molce-40-9-613]; [@b57-molce-40-9-613]; [@b61-molce-40-9-613]; [@b77-molce-40-9-613]). The soluble Aβ oligomers were shown to disrupt cognitive function when injected intracerebroventricularly in rats ([@b14-molce-40-9-613]; [@b77-molce-40-9-613]). Consistent with this, impaired learning and memory were observed in transgenic mice that overexpress full-length human APP751 with the familial Swedish mutation and the Aβ dimer-stabilizing mutation (APS679C), leading to the generation of highly soluble Aβ dimers ([@b63-molce-40-9-613]). The soluble Aβ oligomers rapidly downregulate membrane expression of postsynaptic spine proteins including *N*-methyl-D-aspartate (NMDA) type glutamate and EphB2 receptors, leading to long-term potentiation (LTP) inhibition as well as enhancing long-term depression (LTD; [@b51-molce-40-9-613]; [@b77-molce-40-9-613]). Furthermore, the physiological functions of soluble Aβ40 and Aβ42 have been proposed to be involved in the control of cholesterol *de novo* synthesis and sphingomyelin levels, respectively ([@b31-molce-40-9-613]). Interestingly, proteolytic fragments of APP other than Aβ species were reported to have neuroprotective or neurotoxic activities ([@b10-molce-40-9-613]). Both sAPPα and sAPPβ were shown to mediate neuroprotective function, but the neuroprotective effect of sAPPα was approximately 100 times more potent than sAPPβ ([@b24-molce-40-9-613]). The neuroprotective function of sAPPα is further supported by the finding that sAPPα knock-in mice showed almost complete restoration of the anatomical, behavioral, and electrophysiological abnormalities observed in *APP* knock-out mice ([@b72-molce-40-9-613]). In contrast, neurotoxic sAPPβ activity was also reported in mammals. Neurotrophic factor depletion increases sAPPβ production and further induces proteolytic cleavage of sAPPβ, releasing a cleaved N-terminal fragment, N-APP, which triggers axon degeneration and neuronal cell death through binding to death receptor 6 ([Fig. 1A](#f1-molce-40-9-613){ref-type="fig"}; [@b66-molce-40-9-613]). The AICD, which is produced from both amyloidogenic and non-amyloidogenic pathways ([Fig. 1B](#f1-molce-40-9-613){ref-type="fig"}), has been implicated in the pathological process of AD ([@b65-molce-40-9-613]). AICD overexpression in transgenic mice was shown to induce AD-like pathological features including GSK-3β upregulation, tau hyperphosphorylation and its age-dependent aggregation, and hippocampal neurodegeneration ([@b26-molce-40-9-613]; [@b74-molce-40-9-613]). However, these AD-like phenotypes were not reproduced in independently generated transgenic mice that overexpressed the same AICD ([@b27-molce-40-9-613]), and the cause of this discrepancy remains unclear. In contrast, impaired calcium signaling observed in *APP^−/−^* null-mutant cells can be restored by reintroducing an intact AICD, suggesting its functional role in calcium homeostasis ([@b34-molce-40-9-613]; [@b54-molce-40-9-613]). In addition, AICD overexpression in cultured cells resulted in cell death ([@b62-molce-40-9-613]), and this apoptotic potential of AICD appears to be conserved between humans and *Drosophila* ([@b33-molce-40-9-613]; [@b39-molce-40-9-613]; [@b91-molce-40-9-613]). In summary, soluble Aβ oligomers are now considered to be the primary initiators of neurodegenerative AD processes. In addition, the neurotoxic activity of N-APP and AICD raises the possibility that soluble Aβ oligomers can collaborate with N-APP and AICD to accelerate neurodegeneration in AD patients ([Fig. 3](#f3-molce-40-9-613){ref-type="fig"}). Another possibility is that soluble Aβ oligomers antagonize the neuroprotective functions of sAPPα, sAPPβ, and AICD. One intriguing question is which receptors and signaling components directly respond to soluble Aβ oligomers and result in neuro-degeneration. Therefore, it will be important to identify the crucial genes that link soluble Aβ oligomers to synaptic impairment that correlates with dementia severity in AD.

GENETIC BASIS OF ALZHEIMER'S DISEASE
====================================

The two major types of AD are familial and sporadic ([@b86-molce-40-9-613]). Early-onset familial Alzheimer's disease (EO-FAD), which accounts for less than 5% of AD, is a fully penetrant autosomal-dominant disorder resulting from rare mutations in *APP*, *PS1* and *PS2* ([@b86-molce-40-9-613]). In contrast, late onset sporadic Alzheimer's disease (LO-SAD), which represents most cases of AD, is likely influenced by the combined action of multiple genetic susceptibilities and environmental risk factors ([@b52-molce-40-9-613]). One major genetic risk factor for LO-SAD is the ɛ4 allele of the apolipoprotein E gene (*APOE4*), which plays a crucial role in regulating cholesterol metabolism ([@b15-molce-40-9-613]; [@b82-molce-40-9-613]). The contribution of APOE4 to AD pathogenesis is associated with APOE4-mediated modulation of Aβ aggregation and clearance ([@b6-molce-40-9-613]). Many additional genes have been identified as genetic risk factors for LO-SAD ([@b6-molce-40-9-613]; [@b53-molce-40-9-613]; [@b80-molce-40-9-613]; [@b86-molce-40-9-613]). Although there are differences in the genetic pathological causes between EO-FAD and LO-SAD, they show remarkable similarities in their pathophysiology and clinical symptoms ([@b5-molce-40-9-613]). First, similar patterns of senile Aβ plaques, NFTs, and cerebral amyloid angiopathy are observed in both forms of AD. Second, structural and functional neuroimaging studies indicate that hippocampal and medial-temporal lobe atrophies are commonly found in both types of AD. Third, both AD forms share temporo-parietal hypometabolism and episodic memory and judgment impairment, which are responsible for cognitive deficits. In addition, myoclonus and seizures are also frequently observed. Finally, changes in biochemical markers including cerebrospinal fluid Aβ42, tau, and pTau, during the neurodegeneration process are also very similar in both AD forms. These similarities in neuropathology strongly suggest the presence of common pathogenic biochemical processes underlying both EO-FAD and LO-SAD. Therefore, knowledge and disease-modifying drugs for AD obtained from studies on EO-FAD could be useful in providing preventive treatments for LO-SAD.

To date, a total of 25 pathogenic mutations (except for duplications) in APP associated with EO-FAD have been defined (<http://www.molgen.ua.ac.be/ADMutations/>) ([Fig. 2](#f2-molce-40-9-613){ref-type="fig"}). Most missense mutations in APP are clustered near the proteolytic cleavage sites that are responsible for Aβ generation and clearance ([Fig. 2](#f2-molce-40-9-613){ref-type="fig"}), and they commonly increase the ratio of Aβ42 to Aβ40 ([@b86-molce-40-9-613]). More than 200 mutations in PS1 and 16 in PS2 have been reported to cause EO-FAD (<http://www.molgen.ua.ac.be/ADMutations/>) ([@b86-molce-40-9-613]). Pathogenic missense mutations in *PS1* and *PS2* shift the γ-secretase site from γ40 to γ42, resulting in an increase in the Aβ42 to Aβ40 ratio ([@b19-molce-40-9-613]). Taken together, most missense mutations in *APP*, *PS1*, and *PS2* associated with EO-FAD appear to converge at a higher Aβ42 to Aβ40 ratio, leading to elevated levels of neurotoxic Aβ oligomers, Aβ plaque deposition, and the development of AD.

Although it is widely accepted that the elevated levels of aggregation-prone Aβ including Aβ42 and the longer forms are the primary pathogenic drivers, cognitive impairment in people with AD correlates better with tau pathology than Aβ plaque deposition ([@b36-molce-40-9-613]; [@b81-molce-40-9-613]). Tau is a microtubule-associated protein that regulates the stability of microtubules (MTs) located in axons, thereby contributing to axonal transport and outgrowth ([@b3-molce-40-9-613]). In taupathies including AD, fronto-temporal dementia (FTD), and Parkinsonism, tau is hyperphosphorylated, leading to its disengagement from the MTs and the formation of NFTs ([@b3-molce-40-9-613]). However, mutations in the human tau, *MAPT*, which cause MAPT hyperphosphorylation and aggregation with lack of Aβ deposits, lead to FTD but not to AD ([@b43-molce-40-9-613]). In addition, neocortical NFTs, which are tightly associated with severe cognitive impairment, are consistently found in brains with AD, suggesting that Aβ pathology acts upstream of tau pathology ([@b64-molce-40-9-613]; [@b41-molce-40-9-613]; [Fig. 3](#f3-molce-40-9-613){ref-type="fig"}). Furthermore, reduction in endogenous tau levels prevents behavioral abnormalities and premature mortality observed in the AD mouse model that overexpresses human APP with a familial AD mutation, with no alternation in Aβ plaque deposition ([@b73-molce-40-9-613]). These observations demonstrate that Aβ- and tau-induced neurotoxicity collaborates to cause progressive neurodegeneration and cognitive impairment in AD ([Fig. 3](#f3-molce-40-9-613){ref-type="fig"}).

SYNAPTIC DYSFUNCTION AND NEURONAL CELL DEATH IN ALZHEIMER'S DISEASE
===================================================================

Synapse loss in the neocortex and hippocampus, which play a critical role in learning and memory ([@b46-molce-40-9-613]), is an early pathological hallmark of AD and correlates strongly with cognitive impairment ([@b1-molce-40-9-613]; [@b17-molce-40-9-613]; [@b87-molce-40-9-613]). What are the cellular and molecular mechanisms underlying synapse loss? A great deal of evidence supports that soluble Aβ oligomers contribute to synapse dysfunction and loss by acting on multiple synaptic receptors including NMDA-type glutamate and α7-nicotinic acetylcholine (α7-nACh) receptors ([@b68-molce-40-9-613]; [@b81-molce-40-9-613]). NMDA receptors are required for generating both long-term potentiation and long-term depression but in distinct manners ([@b46-molce-40-9-613]). LTP is a synaptic plasticity mechanism that contributes to memory encoding in the hippocampus ([@b46-molce-40-9-613]); in contrast, LTD in the hippocampus is involved in memory decay ([@b46-molce-40-9-613]). NMDA receptor-induced large Ca^2+^ influx during LTP promotes the incorporation of αamino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-type glutamate receptors into synapses, leading to dendritic spine growth, whereas NMDA receptor-mediated reduced Ca^2+^ influx during LTD decreases the levels of AMPA receptors at the synapses and results in dendritic spine loss ([@b46-molce-40-9-613]). Several studies have shown that soluble Aβ oligomers inhibit LTP and induce progressive spine loss via downregulation of NMDA receptors, followed by synaptic removal of AMPA receptors ([@b11-molce-40-9-613]; [@b16-molce-40-9-613]; [@b40-molce-40-9-613]; [@b76-molce-40-9-613]; [@b90-molce-40-9-613]). In addition, soluble Aβ oligomers interfere with glutamate uptake at the synapses, resulting in enhanced LTD ([@b55-molce-40-9-613]). Consistent with this, NMDA receptor antagonists such as memantine and NitroMemantine can compromise Aβ-induced synaptic dysfunction and cognitive impairment ([@b23-molce-40-9-613]; [@b85-molce-40-9-613]; [@b98-molce-40-9-613]). Taken together, Aβ-mediated LTP inhibition, LTD enhancement, and synapse loss appear to underlie cognitive impairment in AD ([Fig. 3](#f3-molce-40-9-613){ref-type="fig"}; [@b67-molce-40-9-613]).

Soluble Aβ oligomers were shown to activate α7-nACh receptors expressed in *Xenopus* oocytes ([@b21-molce-40-9-613]). Interestingly, α7-nACh receptor blockade reduces the production of Aβ and Aβ-induced synapse loss, indicating the presence of positive feedback between α7-nACh receptors and Aβ ([@b92-molce-40-9-613]). Furthermore, substantial loss of cholinergic neurons in the nucleus basalis of Meynert was observed in AD brains, supporting the cholinergic hypothesis (Bartus et al., 1982; [@b93-molce-40-9-613]). Indeed, cholinesterase inhibitors including donepezil, galantamine, and rivastigmine, which inhibit acetylcholine degradation, are used to treat patients with early-stage AD ([@b9-molce-40-9-613]; [@b98-molce-40-9-613]).

Progressive and substantial neuronal cell death in vulnerable brain regions including the hippocampus, nucleus basalis, and entorhinal cortex is an another pathological hallmark of AD ([@b30-molce-40-9-613]; [@b78-molce-40-9-613]; [@b93-molce-40-9-613]). Consistent with this, significant neuronal loss was observed in many different transgenic mouse models that commonly contain EO-FAD mutations in human full-length APP ([@b95-molce-40-9-613]). In addition, overexpression of N-terminally truncated Aβ~pE3-42~ peptide, which lacks two N-terminal amino acids and carries a pyroglutamate at position 3, but not full-length Aβ42 in transgenic mice induces robust neuronal loss ([@b60-molce-40-9-613]; [@b94-molce-40-9-613]). Because tau abnormalities cause neuronal cell death ([@b25-molce-40-9-613]), these findings suggest that neurotoxic Aβ and tau collaborate to mediate neuronal loss ([Fig. 3](#f3-molce-40-9-613){ref-type="fig"}). Neuronal cell death observed in AD is also associated with mitochondrial dysfunction ([@b49-molce-40-9-613]; [@b69-molce-40-9-613]). Dynamin-related protein 1 was reported to mediate Aβ-related mitochondrial dysfunction and subsequent neuronal loss ([@b13-molce-40-9-613]). In addition, a growing body of evidence suggests that mitochondrial dysfunction plays a critical role in the pathogenesis of AD ([@b70-molce-40-9-613]; [@b84-molce-40-9-613]). Mitochondrial dysfunction in the brains of AD patients correlates with a wide range of mitochondrial abnormalities including mitochondrial DNA defects, decreased levels of mitochondrial enzyme activities, impaired mitochondrial trafficking, and increased oxidative stress ([@b70-molce-40-9-613]; [@b84-molce-40-9-613]). Because mitochondria accumulate reactive oxygen species-induced damage with age, it seems that the most prominent nongenetic risk factor for AD, aging, in concert with soluble Aβ oligomers and pathological tau, contributes to AD pathogenesis through mitochondrial dysfunction ([Fig. 3](#f3-molce-40-9-613){ref-type="fig"}; [@b9-molce-40-9-613]; [@b88-molce-40-9-613]).

CONCLUSION
==========

Tau pathology better correlates with cognitive decline in AD than does substantial Aβ plaque deposition, and the amyloid hypothesis suggests that the tau-mediated formation of NFTs observed in AD results from abnormally elevated Aβ. Recent evidence supports that soluble Aβ oligomers are the primary pathogenic drivers of neurodegeneration in AD and further proposes that soluble Aβ oligomers cooperate with pathological tau to progressively degenerate the learning and memory circuitry required for cognitive functions. In addition to neurotoxic Aβ and tau, the other critical risk factor for clinical onset of AD is aging; age-related mitochondrial damage appears to play an important role in Aβ/tau-induced neurodegeneration in AD. Even though great advances have been made in knowledge of the genetic and cellular mechanisms involved in the pathogenesis of AD, unfortunately, there is still no effective treatment that prevents, delays, and cures it. Therefore, better understanding of the pathological functions of neurotoxic Aβ oligomers and precise mechanisms of Aβ-mediated signaling cascades, in addition to defining the molecular link between Aβ/tau and aging, will help to guide therapeutic drug development for AD treatment.
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![The Regulated Proteolytic Processing of Human β-Amyloid Precursor Protein and the Resulting Cleavage Fragments.\
(A) Schematic diagram of human β-amyloid precursor protein (APP). The arrows represent the cleavage sites by α-, β-, and γ-secretases. GFLD, growth factor-like domain; CuBD, copper-binding domain; Ac, acidic domain; E2, APP extracellular carbohydrate domain; Aβ, amyloid β-peptide; N-APP, a cleaved N-terminal fragment of APP. (B) Human APP can be processed through either amyloidogenic or non-amyloidogenic pathways. In the amyloidogenic pathway (right), the proteolytic cleavage of the APP by β-secretase produces a large soluble ectodomain of APP (sAPPβ) and a membrane-associated C-terminal fragment (C99). The C99 is subsequently cleaved by γ-secretase, releasing an amyloid β-peptide (Aβ) and an APP intracellular domain (AICD). In a non-amyloidogenic pathway (left), α-secretase-mediated cleavage of the APP generates a soluble ectodomain of APP (sAPPα) and a membrane-tethered C-terminal fragment (C83). The subsequent cleavage of the C83 by γ-secretase gives rise to a P3 peptide and an AICD.](molce-40-9-613f1){#f1-molce-40-9-613}

![Human APP Mutations that Cause Familial Alzheimer's Disease.\
The amino acid sequence of the amyloid β-peptide (black box) and flanking transmembrane regions is presented; the horizontal arrows indicate the cleavage sites by α-, β-, andγ-secretases. Many missense and deletion mutations within the APP were discovered to cause an inherited form of Alzheimer's disease.](molce-40-9-613f2){#f2-molce-40-9-613}

![The Main Drivers of Neurodegeneration in Alzheimer's Disease.\
Neuronal dysfunction and cell death are responsible for the development of Alzheimer's disease. Accumulating evidence suggests that abnormally elevated tau hyperphosphorylation, pathogenic Aβ oligomers, and mitochondrial dysfunction cooperate to drive the neuronal dysfunction and cell death that underlie cognitive impairment. Although the amyloid hypothesis supports that neurotoxic Aβ primarily induces tau pathology, other proteolytic fragments of the human APP including sAPPβ, N-APP, and AICD, also appear to contribute to tau alterations. In addition, aging, which is tightly associated with mitochondrial dysfunction, can serve as the most significant nongenetic risk factor for Alzheimer's disease.](molce-40-9-613f3){#f3-molce-40-9-613}
